544445

Standalone Revenue from Operations for the year ended 31st March 2026 was ₹25.47 Cr vs ₹25.04 Cr (▲1.72% YoY). EBITDA was -₹0.57 Cr vs ₹5.44 Cr (▼110.40% YoY). PAT was ₹3.87 Cr vs ₹3.85 Cr (▲0.32% YoY). EBITDA Margin was -2.22% vs 21.71% (▼2393bps). The company reported audited financial results for the year and half year ended 31st March 2026, with auditors issuing an unmodified opinion.

Standalone Annual Revenue for the year ended March 31, 2026, was ₹2,546.88 Lakhs compared to ₹2,503.92 Lakhs in the previous year (▲1.72% YoY). EBITDA was -₹66.95 Lakhs against ₹543.58 Lakhs (▼112.31% YoY). Net Profit (PAT) was ₹386.52 Lakhs compared to ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin contracted significantly from 21.71% to -2.63% (▼2434 bps).

Revenue ₹2,546.88 Lakhs vs ₹2,503.92 Lakhs (▲1.72% YoY), EBITDA ₹555.02 Lakhs vs ₹600.68 Lakhs (▼7.60% YoY), PAT ₹386.52 Lakhs vs ₹385.28 Lakhs (▲0.32% YoY). EBITDA Margin 21.79% vs 23.99% (▼220bps).

ASSTON PHARMACEUTICALS LIMITED announced that a Board Meeting will be held on Friday, 29th May, 2026, at 3:00 P.M. to consider and approve the Audited Financial Statements and Financial Results for the Financial Year and Quarter ended March 31, 2026. The board will also consider the statement of deviation of funds as per SEBI regulations.